Quantinuum Inc. (NASDAQ:QNT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Quantinuum, with 11 buy, 3 hold and 1 sell rating among 15 analysts. The average 12-month price target is $98.42, substantially above the stock’s $49.03 opening price.
• Quantinuum shares have traded between $46.54 and $86.79 over the past year, with the 50-day moving average at $57.37. The company recently reported quarterly revenue of $8 million and an EPS loss of $0.28, missing the $0.26 loss consensus estimate.
• Several institutional investors initiated positions in the second quarter, including Baird Financial Group, Tidal Investments and Outfitters Financial, with disclosed purchases ranging from $409,000 to approximately $1.25 million.

Quantinuum Inc. (NASDAQ:QNT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $98.4167.

Several brokerages have issued reports on QNT. Weiss Ratings started coverage on Quantinuum in a report on Monday, August 31st. They issued a "sell (d)" rating for the company. Craig Hallum began coverage on shares of Quantinuum in a report on Monday, June 29th. They issued a "buy" rating and a $100.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating and set a $90.00 price objective on shares of Quantinuum in a research report on Wednesday, August 12th. UBS Group assumed coverage on shares of Quantinuum in a research note on Monday, June 29th. They set a "buy" rating and a $93.00 target price on the stock. Finally, Mizuho began coverage on shares of Quantinuum in a report on Monday, June 29th. They issued an "outperform" rating and a $90.00 target price on the stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Lisanti Capital Growth LLC acquired a new stake in Quantinuum during the second quarter worth $409,000. Integrated Wealth Concepts LLC acquired a new position in shares of Quantinuum in the 2nd quarter valued at $417,000. Outfitters Financial LLC purchased a new position in shares of Quantinuum during the 2nd quarter worth $511,000. Tidal Investments LLC purchased a new position in shares of Quantinuum during the 2nd quarter worth $1,122,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of Quantinuum during the 2nd quarter worth about $1,251,000.

Quantinuum Stock Performance

Shares of Quantinuum stock opened at $49.03 on Friday. The business's 50 day moving average is $57.37. Quantinuum has a 1-year low of $46.54 and a 1-year high of $86.79.

Quantinuum (NASDAQ:QNT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $8.00 million during the quarter. As a group, analysts expect that Quantinuum will post -1.64 earnings per share for the current fiscal year.

About Quantinuum

Quantinuum is a quantum computing and technology company formed in 2021 through the combination of Honeywell Quantum Solutions and Cambridge Quantum. The company develops integrated quantum computing systems, combining quantum hardware, software and applications for business, government and research customers.

Its offerings include trapped-ion quantum computers in the H-Series, quantum software development tools such as TKET, and cybersecurity products including Quantum Origin, which is designed to help generate and protect cryptographic keys.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.